en En

Spotlight Interviews

CDD Spotlight Interview with Paul Humphries, Reset Therapeutics

"As a company we all have to have a phenotypic drug discovery mindset, which means that we have to be prepared for any target (or working on an unknown target) that acts through any compartment (liver, CNS, etc) that modulates physiological endpoints for any disease. I’m no longer a target-based medicinal chemist working on metabolic diseases, I’m a phenotypic drug discovery scientist working on circadian modulators that are disease agnostic. It’s an exciting, challenging and hugely rewarding part of my career and I am relishing working with the Reset team to create a new path for drug discovery in this novel scientific area."
Read Interview

Prof. Jonathan Baell of “PAINS” Filters Fame from Monash University

Baell CDD
"People are just finding compounds with a bit of activity and really publishing screening hits as though they are genuine optimizable candidates. And these things can be subversive and they can look real, so these publications are kind of getting accepted and unfortunately there's a lot of noise out there, a lot of pollution, and this is one of the things we certainly strive to do here is not to publish something for the sake of publishing, but to publish it after making optimizations showing these are absolutely real."
Read Interview

Dr. Robert Volkmann, Vice President of Chemistry – Mnemosyne & SystaMedic

Robert Bob Volkmann
"What you've done is you've designed a product that works for people like me. It not only works great for me but also works great for our biologists and our CRO chemists in India. ... I just take it for granted that CDD Vault will work and it will work as planned. So I guess for me the test for the value of something is that you can use it without ever thinking about it."
Read Interview

Orphagen CEO Scott Thacher, Ph.D. + Director of Chemistry Ruo Steensma, Ph.D.

Scott Thacher Ruo Steensma
"We had Excel sheets all over the place and data from different projects that were just separated in different folders and after a while," says Dr. Ruo Steensma, "It got to the point that it was just hard to manage. We chose CDD, and we’re really happy with the service and the cost and the way the database is evolving."
Read Interview

Scott Myers, Ph.D., Director of Drug Discovery – NeurOp, Inc.

Scott Myers CDD
"I recall early on trying to understand what should I do if I’m interested in science, but I’m not interested in medicine so to speak, like, being a medical doctor. And I was reading some descriptions about pharmacology and then I realized that sounded pretty exciting and also fit what I really thought I would like to do. That took me to pharmacy school. And in pharmacy school, I really realized I was more interested in the research and so I went the research path… That was over 20 years ago. And between then and now (when I got this job at NeurOp) NeurOp was really what I always wanted to do. I think this level of the in-vitro pharmacology and evaluating novel molecules has always been my main interest."
Read Interview

Dr. David Matthews, Pathway Therapeutics, Vice President, Drug Discovery and Exploratory Development

David Mathews
"So I actually started out life as a physicist. My undergraduate degree was physics and during that time my undergraduate tutor was Professor David Blow, who was at Imperial College where I did my degree. He was one of the pioneers of x-ray crystallography, sadly passed away a few years ago, but I would say that David was certainly instrumental in fostering my interest in biology and as I went through my undergraduate degree, I realized that this was a field that was fascinating to me, that I really wanted to get into. So I guess that would be the first turning point was in making the decision to mutate from a physicist into a biologist."
Read Interview

Send this to a friend